<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "irinotecan inj VIAL">
<dose><value>165</value>
<value>350</value>
<value>280</value>
<value>250</value>
<value>180</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>20 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction><value>Administer dose diluted in 500 mL D5W over 90 minutes.</value>
</instruction>
<volume><value>2 mL</value>
<value>5 mL</value>
</volume>
<units><value>mg/m2</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Metastatic Colorectal Cancer</value>
<value>Metastatic Colorectal Cancer. For patients 70 years or older, or in patients with prior pelvic RT, start dose at 80%.</value>
<value>Metastatic Colorectal Cancer. 80% dose of 350 mg/m2; suggested for patients 70 years or older, or in patients with prior pelvic RT.</value>
<value>Metastatic Colorectal Cancer.</value>
<value>Metastatic Colorectal Cancer, Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer, Metastatic Pancreatic Cancer. Dose to run concurrently with leucovorin order (FOLFIRI protocol).</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3404</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>